Abstract

Short Perspective

Call to Action! Hypertension and Dyslipidemia in Mexico: Underestimated Deadly Duo

Martin Rosas-Peralta, Héctor Galván-Oseguera, Luis Alcocer, Humberto Álvarez-López, Ernesto Cardona-Muñoz, Silvia Palomo-Piñón, Enrique Díaz-Díaz, Adolfo Chávez-Mendoza and José Manuel Enciso-Muñoz

Published: 11 December, 2024 | Volume 8 - Issue 1 | Pages: 007-010

Background: High blood pressure and dyslipidemia are risk factors that begin silently and share many pathophysiological mechanisms of tissue damage.
Aim: Draw attention to this binomial (Hypertension and dyslipidemia) that is highly prevalent in Mexico and is mainly responsible for the leading atherothrombotic process as a cause of death in Mexico and the world.
Methods: Reflective analysis of the evidence accumulated in the last 20 years. We launch key messages and support why every hypertensive patient should be treated with a statin.
Results: We call for awareness to measure lipid levels and blood pressure twice a year from the age of 20 and to detect these devastating nosological entities as soon as possible. We remove the myth that PCSK9 inhibitors as well as the small interfering RNA of its synthesis are only for familial dyslipidemia. Measurement of serum Lp(a) should be routine, especially if you have a history of your own and family cardiovascular events.
Conclusion: We should be aware of the little impact that health strategies have had to stop the main cause of death in Mexico. Every hypertensive patient should receive a statin, even if their serum LDLc levels are apparently normal. The great challenge of optimal control of the population with hypertension and/or dyslipidemia continues. The small interfering RNA synthesis PCSK9 should also be considered when conventional therapies are not sufficient and this situation is not infrequent.

Read Full Article HTML DOI: 10.29328/journal.ach.1001036 Cite this Article Read Full Article PDF

Keywords:

Arterial hypertension; Dyslipidemia; Atherothrombosis; Statins; iPSCK9; Inclisiran

References

  1. Causes of death in Mexico. INEGI 2023. Available from: https://www.inegi.org.mx/app/buscador/default.html?q=causas+de+muerte+2023
  2. The Burden of Cardiovascular Diseases. WHO. Available from: https://www.paho.org/es/enlace/carga-enfermedades-cardiovasculares
  3. Sectorial program derived from the national development plan 2019-2024. Mexico. Available from: https://climate-laws.org/document/national-development-plan-2019-2024_9f22
  4. Rosas-Peralta M. Cardio-Reno-Metabolic-Neurological Connection “CARMEN”; in: Manual for the certification of health personnel of the first contact on the care of patients with hypertension. ASECOM Eds. 2024. ISBN 978-607-59590-4-7.
  5. Rosas-Peralta M, Galván-Oseguera H, Velasquez-Vélez T, Borrayo-Sánchez G. Dyslipidemia as an associated risk factor in hypertensive women. Cardiovasc Metab Sci. 2024;35:s15-s17. Available from: https://www.medigraphic.com/pdfs/cardiovascuar/cms-2024/cmss241d.pdf
  6. Palomo-Pinon S, Antonio-Villa N, Garcia-Cortés L, Alcocer L, Alvarez-Lopez H, Cardona-Muñoz E, et al. Patients living with arterial hypertension in Mexico: first insights of The Mexican Registry of Arterial Hypertension (RIHTA Study). Am J Hypertens. 2024;37(7):503-513. Available from: https://doi.org/10.1093/ajh/hpae024
  7. Kovach ChP, Mesenbring EC, Gupta P, Glorioso TJ, Ho M, Waldo SW, et al. Projected outcomes of optimized statin and ezetimibe therapy in US military veterans with coronary artery disease. JAMA Netw Open. 2023;6(8):e2329066. Available from: https://doi.org/10.1001/jamanetworkopen.2023.29066
  8. Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh M. A comprehensive review of PCSK9 inhibitors. J Cardiovasc Pharmacol Ther. 2022;27:10742484221100107. Available from: https://doi.org/10.1177/10742484221100107
  9. Shetty NS, Gaonkar M, Patel N, Knowles JW, Natarajan P, Arora G, Arora P. Trends of lipid concentrations, awareness, evaluation, and treatment in severe dyslipidemia in US adults. Mayo Clin Proc. 2024;99(2):271-282. Available from: https://doi.org/10.1016/j.mayocp.2023.09.016
  10. Aygun S, Tokgozoglu L. Comparison of current international guidelines for the management of dyslipidemia. J Clin Med. 2022;11(23):7249. Available from: https://doi.org/10.3390/jcm11237249
  11. Ascasoa JF, Civeira Fb, Guijarroc J, López JM, Mansana L, Mostaza JM, et al. Indications for PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. Clin Investig Arterioscler. 2019;31(3):128-139. Available from: https://doi.org/10.1016/j.arteri.2019.04.002
  12. Duarte Lau F, Giugliano RP. Lipoprotein(a) and its significance in cardiovascular disease: A review. JAMA Cardiol. 2022 Jul 1;7(7):760-769. Available from: https://doi.org/10.1001/jamacardio.2022.0987
  13. Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-e60. Available from: https://doi.org/10.1161/atv.0000000000000147
  14. Backes JM. Lipoprotein(a) and cardiovascular risk. US Pharm. 2023;48(11):17-23. Available from: https://researchworks.creighton.edu/esploro/outputs/journalArticle/Lipoproteina-and-Cardiovascular-Risk/991006058770802656
  15. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925–3946. Available from: https://doi.org/10.1093/eurheartj/ehac361
  16. Vinci P, Di Girolamo FG, Panizon E, Tosoni LM, Cerrato C, Pellicori F, et al. Lipoprotein(a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives. Int J Environ Res Public Health. 2023;20(18):6721. Available from: https://doi.org/10.3390/ijerph20186721
  17. Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532,359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36(11):2239-2245. Available from: https://doi.org/10.1161/atvbaha.116.308011
  18. Ishiyama Y, Hoshide S, Kario K. Systemic hemodynamic atherothrombotic syndrome: from hypothesis to evidence. Hipertens Res. 2024;47:579–585. Available from: https://doi.org/10.1038/s41440-023-01459-9
  19. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. Available from: https://doi.org/10.1056/nejmoa1912387

Figures:

Similar Articles

  • Cardiovascular risk reduction: Past, present and future in Mexico
    Gabriela Borrayo-Sánchez*, Martin Rosas-Peralta, Erick Ramírez-Arias, Gladys M Jiménez-Genchi, Martha Alicia Hernández-Gonzále, Rafael Barraza-Félix, Lidia Evangelina Betacourt-Hernández, ocio Camacho-Casillas, Rodolfo Parra-Michel, Héctor David Martínez Chapa and José de Jesús Arriaga-Dávila Gabriela Borrayo-Sánchez*,Martin Rosas-Peralta,Erick Ramírez-Arias,Gladys M Jiménez-Genchi,Martha Alicia Hernández-Gonzále,Rafael Barraza-Félix,Lidia Evangelina Betacourt-Hernández,ocio Camacho-Casillas,Rodolfo Parra-Michel,Héctor David Martínez Chapa,José de Jesús Arriaga-Dávila. Cardiovascular risk reduction: Past, present and future in Mexico. . 2018 doi: 10.29328/journal.ach.1001010; 2: 038-047
  • Heart Failure with preserved Ejection Fraction (HFpEF); A Mexican cohort from Mexican Institute of Social Security (IMSS)
    Martin Rosas Peralta*, Lizette Arizmendi-Ocampo, Daniela Salinas Morales, Alicia Contreras Rodríguez, Erick Ramírez Arias, Carlos Riera kinkel, Guadalupe Castro Martínez, José Antonio Magaña-Serrano and Alejandro Chanona Espinosa Martin Rosas Peralta*,Lizette Arizmendi-Ocampo,Daniela Salinas Morales,Alicia Contreras Rodríguez,Erick Ramírez Arias,Carlos Riera kinkel,Guadalupe Castro Martínez,José Antonio Magaña-Serrano, Alejandro Chanona Espinosa. Heart Failure with preserved Ejection Fraction (HFpEF); A Mexican cohort from Mexican Institute of Social Security (IMSS). . 2019 doi: 10.29328/journal.ach.1001014; 3: 001-008
  • Hypertension as a persistent public health problem. A position paper from Alliance for a Healthy Heart, Mexico
    Martin Rosas-Peralta*, Luis Alcocer, Humberto Álvarez-López, Gabriela Borrayo-Sánchez, Ernesto Germán Cardona-Muñoz, Adolfo Chávez-Mendoza, Enrique Díaz y Díaz, José Manuel Enciso-Muñoz, Héctor Galván-Oseguera, Enrique Gómez-Álvarez, Pedro Gutiérrez-Fajardo, Héctor Hernández y Hernández, Francisco Javier León-Hernández, José Antonio Magaña-Serrano and José Zacarías Parra-Carrillo Martin Rosas-Peralta*,Luis Alcocer,Humberto Álvarez-López,Gabriela Borrayo-Sánchez,Ernesto Germán Cardona-Muñoz,Adolfo Chávez-Mendoza,Enrique Díaz y Díaz,José Manuel Enciso-Muñoz,Héctor Galván-Oseguera,Enrique Gómez-Álvarez,Pedro Gutiérrez-Fajardo,Héctor Hernández y Hernández,Francisco Javier León-Hernández,José Antonio Magaña-Serrano,José Zacarías Parra-Carrillo. Hypertension as a persistent public health problem. A position paper from Alliance for a Healthy Heart, Mexico. . 2019 doi: 10.29328/journal.ach.1001015; 3: 009-030
  • Left ventricular hypertrophy linked with arterial hypertension through centralized aerobic-anaerobic energy balance compensation theory
    Kirill V Zhukov, Bagrat A Gasparyan, Alexandre A Vetcher* and Alexander Y Shishonin Kirill V Zhukov,Bagrat A Gasparyan,Alexandre A Vetcher*,Alexander Y Shishonin. Left ventricular hypertrophy linked with arterial hypertension through centralized aerobic-anaerobic energy balance compensation theory. . 2022 doi: 10.29328/journal.ach.1001030; 6: 012-014
  • Call to Action! Hypertension and Dyslipidemia in Mexico: Underestimated Deadly Duo
    Martin Rosas-Peralta, Héctor Galván-Oseguera, Luis Alcocer, Humberto Álvarez-López, Ernesto Cardona-Muñoz, Silvia Palomo-Piñón, Enrique Díaz-Díaz, Adolfo Chávez-Mendoza and José Manuel Enciso-Muñoz Martin Rosas-Peralta,Héctor Galván-Oseguera,Luis Alcocer,Humberto Álvarez-López,Ernesto Cardona-Muñoz,Silvia Palomo-Piñón,Enrique Díaz-Díaz,Adolfo Chávez-Mendoza,José Manuel Enciso-Muñoz. Call to Action! Hypertension and Dyslipidemia in Mexico: Underestimated Deadly Duo. . 2024 doi: 10.29328/journal.ach.1001036; 8: 007-010

Recently Viewed

Read More

Most Viewed

Read More

Help ?